Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy
ConclusionThe timing of the infusion of nivolumab may affect treatment efficacy in R/M-ESCC.
Source: Esophagus - Category: Gastroenterology Source Type: research
More News: Cancer & Oncology | Carcinoma | Esophagus Cancer | Gastroenterology | Skin Cancer | Squamous Cell Carcinoma | Study